

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Last Update: Apr 23, 2025

An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov Identifier:

[NCT05275868](#)

Novartis Reference Number:CMGY825A12101

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer. First in human, phase I, multicenter, open-label study of MGY825 single agent with a dose escalation and a dose expansion in adult patients with advanced non-small cell lung cancer (NSCLC).

The dose escalation part will investigate the safety and tolerability of MGY825 in adult patients with advanced NSCLC harboring NFE2L2, or KEAP1 or CUL3 (NFE2L2/KEAP1/CUL3) mutations. Patient enrollment will be based on locally available test results of mutation status.

An exploratory assessment on the effect of food may be investigated during the dose escalation part.

The dose expansion part will assess the preliminary anti-tumor activity and further assess the safety and tolerability of MGY825 in adult patients with advanced NSCLC divided in two patient groups.

Group 1: Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status.

Group 2: Patients with advanced NSCLC irrespective of prior knowledge of NFE2L2/KEAP1/CUL3 mutational status.

Condition

Non-small Cell Lung Cancer

Phase

Phase1

Overall Status

Recruiting

Number of Participants

140

Start Date

Oct 05, 2022

Completion Date

Jul 28, 2027

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug

MGY825

investigational drug

Eligibility Criteria

Inclusion Criteria:

- * Signed informed consent must be obtained prior to participation in the study.
- * Dose escalation and dose expansion group 1:

Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NFE2L2/KEAP1/CUL3 mutant NSCLC. Local data confirming the NFE2L2/KEAP1/CUL3 mutation status in tissue must be available for enrollment.

- * Dose expansion group 2:

Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NSCLC irrespective of NFE2L2/KEAP1/CUL3 mutation status.

- * All patients:

Patients must have progressed after 1 platinum-based chemotherapy regimen and PD-(L)1 antibody therapy either sequentially or concurrent with chemotherapy, where indicated, for Stage IV NSCLC.

Patients treated with neo-adjuvant / adjuvant platinum-based therapy that progressed within 6 months of treatment are permitted to participate.

Prior therapy with VEGF/VEGFR targeting agents is permitted. Prior treatment with approved targeted drugs (e.g., EGFRi, ALKi, METi) is mandatory in patients with NSCLC whose tumor bears actionable mutations.

- * Presence of at least one measurable lesion according to RECIST v1.1.
- * Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during study treatment. A recent biopsy collected after the last systemic treatment and within 3 months before study entry may be submitted at screening.

Exclusion Criteria:

- * Having out of range laboratory values defined as:

Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \leq 60 mL/min Total bilirubin \geq 2/6

1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin $\geq 3.0 \times \text{ULN}$ or direct bilirubin $\geq 1.5 \times \text{ULN}$ ALT $\geq 3 \times \text{ULN}$ AST $\geq 3 \times \text{ULN}$ ANC $\geq 1.0 \times 10^9/\text{L}$ Platelet count $\geq 75 \times 10^9/\text{L}$ Hemoglobin $\geq 9 \text{ g/dL}$

* Impaired cardiac function or clinically significant cardiac disease, including any of the following:

Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥ 2), uncontrolled hypertension or clinically significant arrhythmia.

QTcF $\geq 470 \text{ msec}$ on screening ECG or congenital long QT syndrome. Acute myocardial infarction or unstable angina pectoris ≥ 3 months prior to study entry.

* Presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery) or increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with treated symptomatic brain metastases should be neurologically stable (for 4 weeks post-treatment and prior to study entry) and at a dose of $\leq 10 \text{ mg}$ per day prednisone or equivalent for at least 2 weeks before administration of any study treatment.

* Known active COVID-19 infection.

* Unable or unwilling to swallow capsules as per dosing schedule. Other protocol-defined inclusion/exclusion criteria may apply.

Germany

Novartis Investigative Site

Recruiting

Frankfurt am Main, Hessen, 60590, Germany

Novartis Investigative Site

Recruiting

Essen, 45147, Germany

Japan

Novartis Investigative Site

Recruiting

Chuo ku, Tokyo, 104 0045, Japan

Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul, 03080, Korea, Republic of

Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

Novartis Investigative Site

Recruiting

Madrid,28050,Spain

Switzerland

Novartis Investigative Site

Recruiting

Geneve 14,Ch 1211,Switzerland

Novartis Investigative Site

Recruiting

St Gallen,9007,Switzerland

United States

Dana Farber Cancer Institute

Recruiting

Boston,Massachusetts,02115,United States

Rebecca Rivenburgh

Phone: 617-632-5136

Email: Rebecca_Rivenburgh@DFCI.HARVARD.EDU

Biagio Ricciuti

Memorial Sloan Kettering Onc. Dept

Recruiting

New York,New York,10017,United States

Paul Paik

Phone: 646-608-3759

Email: paikp@mskcc.org

Paul Paik

NYU School of Medicine

Recruiting

New York, New York, 10015, United States

Cesar Diaz

Email: Cesar.Diaz@nyulangone.org

Vamsidhar Velcheti

Uni Of TX MD Anderson Cancer Cntr

Recruiting

Houston, Texas, 77030, United States

Ferdinand Skoulidis

Shari A Daniels

Phone: [713-792-2921](tel:713-792-2921)

Email: sadaniels@mdanderson.org

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, 02114, United States

Brian Kelter

Email: bkelter@partners.org

Jessica Jiyeong Lin

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05275868>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05275868>
2. [#trial-eligibility](#)
3. tel:617-632-5136
4. mailto:Rebecca_Rivenburgh@DFCI.HARVARD.EDU
5. tel:646-608-3759
6. <mailto:paikp@mskcc.org>
7. <mailto:Cesar.Diaz@nyulangone.org>
8. tel:713-792-2921
9. <mailto:sadaniels@mdanderson.org>
10. <mailto:bkelter@partners.org>
11. tel:+41613241111
12. <mailto:novartis.email@novartis.com>
13. tel:1-888-669-6682
14. <mailto:novartis.email@novartis.com>